Log In
BCIQ
Print this Print this
 

Lu AF35700

  Manage Alerts
Collapse Summary General Information
Company H. Lundbeck A/S
DescriptionAntipsychotic that binds dopamine D1 and serotonin (5-HT2A) and 5-HT6 receptors
Molecular Target Dopamine D1 receptor ; Serotonin (5-HT) receptor
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia; Treat treatment-resistant schizophrenia
Regulatory Designation U.S. - Fast Track (Treat treatment-resistant schizophrenia)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today